Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients

被引:109
作者
Canavese, C
Bergamo, D
Ciccone, G
Longo, F
Fop, F
Thea, A
Martina, G
Piga, A
机构
[1] Univ Turin, S Giovanni Molinette Hosp, Dept Internal Med, Nephrol Sect, Turin, Italy
[2] Univ Turin, S Giovanni Molinette Hosp, Dept Pediat Sci, Turin, Italy
[3] Univ Turin, S Giovanni Molinette Hosp, Canc Epidemiol Unit, Turin, Italy
[4] OIRM CTO Hosp, Turin, Italy
关键词
ferritin; transferrin saturation; iron overload; uremia; magnetic susceptometry; gender;
D O I
10.1111/j.1523-1755.2004.00480.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Guidelines for treating anemia in dialysis patients accept, as high-end range of serum ferritin useful to optimize erythropoietin therapy, values high as 500 to 900 mug/L, on the hypothesis that ferritin might be not representative of iron overload. Methods. A superconducting quantum interference device (SQUID) was used to make direct noninvasive magnetic measurements of nonheme hepatic iron content in 40 dialysis patients treated with intravenous iron, and liver iron content was compared with biochemical markers of iron status. Results. Only 12/40 (30%) patients showed normal hepatic iron content (SQUID < 400 mu g/g), while 32.5% had mild (400 to 1000 mu g/g) and 37.5% severe (1000 mu g/g) iron overload, although 28/40 patients (70%) had serum ferritin below 500 mu g/L. Among many parameters, hepatic iron content was only correlated with ferritin (r = 0.324, P = 0.04). The receiver operating characteristic (ROC) analysis showed the best specificity/ sensitivity ratio to identify iron overload for ferritin > 340 mug/L (W = 0.716). Multivariate logistic regression analysis demonstrated that an increase in serum ferritin of 100 mug/L and female gender were independent variables associated with moderate to severe hepatic iron overload: OR 1.71 (95% CI 1.10 to 2.67) and OR 10.68 (95% CI 1.81 to 63.15), respectively. Conclusion. Hepatic iron overload is frequent in dialysis patients with ferritin below currently proposed high-end ranges, and the diagnostic power of ferritin in indicating true iron stores is better than presumed. Safety concerns should prompt a reevaluation of acceptable iron parameters, focusing on potential gender-specific differences, to avoid potentially harmful iron overload in a majority of dialysis patients, mainly females.
引用
收藏
页码:1091 / 1098
页数:8
相关论文
共 48 条
[11]   Theoretical evaluation of the susceptometric measurement of iron in human liver by four different susceptometers [J].
Carneiro, AAO ;
Baffa, O ;
Fernandes, JP ;
Zago, MA .
PHYSIOLOGICAL MEASUREMENT, 2002, 23 (04) :683-693
[12]   Iron and erythropoietin in renal disease [J].
Cavill, I .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2002, 17 :19-23
[13]   Iron status as measured by serum ferritin: The marker and its limitations [J].
Cavill, I .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (04) :S12-S17
[14]   Diagnosis of juvenile hemochromatosis in an 11-year-old child combining genetic analysis and non-invasive liver iron quantitation [J].
De Gobbi, M ;
Caruso, R ;
Daraio, F ;
Chianale, F ;
Pinto, RM ;
Longo, F ;
Piga, A ;
Camaschella, C .
EUROPEAN JOURNAL OF PEDIATRICS, 2003, 162 (02) :96-99
[15]  
Della Penna S, 1999, PHYS MED BIOL, V44, pN21, DOI 10.1088/0031-9155/44/3/005
[16]   Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: A multicenter, prospective, randomized, controlled trial [J].
Di Bisceglie, AM ;
Bonkovsky, HL ;
Chopra, S ;
Flamm, S ;
Reddy, RK ;
Grace, N ;
Killenberg, P ;
Hunt, C ;
Tamburro, C ;
Tavill, AS ;
Ferguson, R ;
Krawitt, E ;
Banner, B ;
Bacon, BR .
HEPATOLOGY, 2000, 32 (01) :135-138
[17]   Indices of iron status in continuous ambulatory peritoneal dialysis patients [J].
Domrongkitchaiporn, S ;
Jirakranont, B ;
Atamasrikul, K ;
Ungkanont, A ;
Bunyaratvej, A .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1999, 34 (01) :29-35
[18]   Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease [J].
Drüeke, T ;
Witko-Sarsat, V ;
Massy, Z ;
Descamps-Latscha, B ;
Guerin, AP ;
Marchais, SJ ;
Gausson, V ;
London, GM .
CIRCULATION, 2002, 106 (17) :2212-2217
[19]   Cardiovascular consequences of renal anaemia and erythropoietin therapy [J].
Eckardt, KU .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1999, 14 (05) :1317-1323
[20]  
Eckardt KU, 2000, CLIN NEPHROL, V53, pS2